Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Financing Activities: 2013-2025

Historic Cash from Financing Activities for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $159.7 million.

  • KalVista Pharmaceuticals' Cash from Financing Activities fell 96.90% to $4.7 million in Q2 2025 from the same period last year, while for Apr 2025 it was $158.1 million, marking a year-over-year increase of 4.87%. This contributed to the annual value of $159.7 million for FY2025, which is 5.98% up from last year.
  • KalVista Pharmaceuticals' Cash from Financing Activities amounted to $159.7 million in FY2025, which was up 5.98% from $150.7 million recorded in FY2024.
  • In the past 5 years, KalVista Pharmaceuticals' Cash from Financing Activities registered a high of $212.1 million during FY2021, and its lowest value of $1.6 million during FY2022.
  • Over the past 3 years, KalVista Pharmaceuticals' median Cash from Financing Activities value was $150.7 million (recorded in 2024), while the average stood at $122.9 million.
  • In the last 5 years, KalVista Pharmaceuticals' Cash from Financing Activities tumbled by 99.25% in 2022 and then soared by 3,575.90% in 2023.
  • Over the past 5 years, KalVista Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $212.1 million in 2021, then crashed by 99.25% to $1.6 million in 2022, then surged by 3,575.90% to $58.1 million in 2023, then surged by 159.33% to $150.7 million in 2024, then rose by 5.98% to $159.7 million in 2025.